07 December 2020


Rheumatology would like to say a huge thanks to everyone who has contributed to or read the JAK inhibitors supplement. Downloaded more than 51,000 times, all of its papers feature in Rheumatology's top 700 (of 19,000!) most downloaded papers. Meanwhile, two thirds of its papers are flagged as ‘highly cited’ in Clarivate’s Web of Science (167 to date).


Guest-edited by Prof Yoshiya Tanaka from University of Occupational and Environmental Health, Japan, the supplement covers topics including basic insights and clinical practice, efficacy, safety, and drugs under development.


Prof Tanaka says: "It's my great pleasure and honour to be involved in putting together this supplement for Rheumatology, and to contribute to the progression of knowledge in this area”.


Dr Marwan Bukhari, Rheumatology Editor in Chief adds: "The value of supplements like this is to concentrate the evidence behind the growing body of work showing that these compounds are a significant shift in the way we treat rheumatic diseases. Supplements always provide a good overview of a specific area within rheumatology and can educate and update our readership. They're rigorously peer reviewed and guest edited as well in order to ensure the top experts in the field are involved in the curation and publication process. They're well received, cited, quoted and tweeted."


A particular congratulations to Dr George E Fragoulis, Prof Iain B McInnes, and Prof Stefan Siebert, whose paper 'JAK-inhibitors: new players in the field of immune-mediated diseases, beyond rheumatoid arthritis' is, at more than 23,000, Rheumatology’s 10th most downloaded paper ever.


Rheumatology publisher Francesca Cockshull says: "We're thrilled with the reception of this supplement and once again thank everyone who has worked to make it a success."


If you have an idea for a supplement or article, please contact the Rheumatology or Rheumatology Advances in Practice Editorial Offices at editorial@rheumatology.org.uk and rap.editorial@rheumatology.org.uk respectively. We're always keen to hear new suggestions!